Innovate Corporation's MediBeacon TGFR System Wins FDA Approval

Reuters12-16
Innovate Corporation's MediBeacon TGFR System Wins FDA Approval

Innovate Corporation announced that MediBeacon Inc., in which Innovate holds a 44.7% equity interest, has received FDA approval for the next generation MediBeacon® TGFR™ System, including the latest TGFR™ Reusable Sensor. This first-in-kind device enables point-of-care kidney function assessment using transdermal GFR technology. Initial commercialization at select academic medical centers in the United States and China is expected to begin in early 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovate Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9602760) on December 16, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment